What is Evaluate?
Founded in 1996 and headquartered in Greater London, Evaluate has spent over two decades refining the art of collecting, calibrating, and connecting complex pharmaceutical data. The company serves as a vital bridge between raw clinical information and actionable commercial strategy, enabling pharmaceutical and medical device firms to navigate the complexities of drug development and market access. By providing trusted, data-driven insights, Evaluate empowers decision-makers to mitigate risk and optimize their portfolios in an increasingly volatile global market. Its platform is widely regarded as an essential tool for enterprise-level strategic planning, offering a unique synthesis of historical performance data and predictive market modeling.
How much funding has Evaluate raised?
Evaluate has raised a total of $10.6M across 1 funding round:
Private Equity
$10.6M
Private Equity (2020): $10.6M with participation from HgCapital Trust
Key Investors in Evaluate
HgCapital Trust
A prominent investment trust focused on long-term capital appreciation through investments in unquoted companies, particularly within the software and technology-enabled services sectors.
What's next for Evaluate?
Following this major enterprise-level funding, Evaluate is positioned to accelerate its technological roadmap and expand its footprint in the digital health analytics space. The infusion of capital will likely be directed toward enhancing the scalability of its data processing engines and deepening its integration with emerging AI-driven forecasting tools. As the pharmaceutical industry faces mounting pressure to demonstrate value-based outcomes, Evaluate's ability to provide granular, reliable intelligence will be paramount. The company is expected to leverage this financial momentum to explore strategic partnerships and potentially broaden its service offerings, ensuring it remains at the vanguard of the life sciences intelligence market for years to come.
See full Evaluate company page
